Study aims to uncover how often COVID-19 leads to permanent lung damage
NCT ID NCT04987528
First seen Feb 02, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This study follows 200 patients who had severe COVID-19 pneumonia to see how many develop lung scarring (pulmonary fibrosis). Researchers will use blood tests and CT scans to detect early signs of scarring and identify risk factors. The goal is to better understand the long-term lung damage caused by severe COVID-19.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Hopital Europeen Marseille
Marseille, 13003, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors predict and monitor lung scarring after severe COVID-19, improving follow-up care.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or therapy, so direct patient benefits are limited.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.